# US 2020/0400670 A1 · Methods and compositions for live cell analysis of intracellular atp

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400670 A1
- Document ID: US20200400670A1
- Status: Published application
- Kind: A1
- Application number: 16/765,908
- Filed: 2019-03-07
- Published: 2020-12-24
- Earliest claimed: 2018-03-09
- Assignees: Sartorius BioAnalytical Instruments, Inc.
- Applicants: Essen Instruments, Inc. D/B/A Essen Bioscience, Inc.
- Inventors: Daniel APPLEDORN; Cicely SCHRAMM; Grigory FILONOV; Kirk SCHROEDER
- Web page: https://patentgrep.com/patent/US20200400670A1

## CPC

- G01N 33/5735: {co-enzymes or co-factors, e.g. NAD or ATP}
- C07K 1/082: {containing phosphorus}
- C12N 9/14: Hydrolases (3)
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/582: {with fluorescent label}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12Q 2563/107: fluorescence
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are ATP biosensor fusion proteins and their use for assaying ATP levels in cells.

## Claims

### Claim 1

A fusion protein, comprising a polypeptide of genus X1-X2-X3-X4-X5, wherein:
one of X1 and X5 comprises a fluorescence resonance energy transfer (FRET) acceptor polypeptide having an acceptor excitation wavelength and FRET emission wavelength, and the other of X1 and X5 comprises a FRET donor polypeptide having a donor excitation wavelength and a donor emission wavelength
X2 and X4 independently are optional amino acid linkers; and
X3 comprises an ATP binding protein;
wherein binding of ATP by the ATP binding protein causes interaction of the FRET acceptor polypeptide and the FRET donor polypeptide.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein X1 comprises a FRET acceptor polypeptide and X5 comprises a FRET donor polypeptide.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein X1 comprises a FRET donor polypeptide and X5 comprises a FRET acceptor polypeptide.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein X2 is an amino acid linker of between 1-2 amino acids in length, or is absent.

### Claim at position 5

-6. (canceled)

### Claim 7 (depends on 1)

The fusion protein of claim 1, wherein X2 is an amino acid linker selected from the group consisting of A, S, P, V, T, TS, ID, or wherein X2 is absent.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 1)

The fusion protein of claim 1, wherein X4 is an amino acid linker of between 1-5 amino acids in length, or wherein X4 is absent.

### Claim at position 9

-12. (canceled)

### Claim 13 (depends on 1)

The fusion protein of claim 1, wherein X4 is an amino acid linker selected from the group consisting of AT, A, SA, GA, FF, PPPP (SEQ ID NO: 20), FL, GTSG (SEQ ID NO: 21), P, S, ANEFM (SEQ ID NO: 22), or wherein X4 is absent.

### Claim at position 11

-21. (canceled)

### Claim 22 (depends on 1)

The fusion protein of claim 1, wherein X2 and X4 do not include any proline residues.

### Claim 23 (depends on 1)

The fusion protein of claim 1, wherein the FRET acceptor polypeptide has a maximal acceptor excitation wavelength in a range of 500 to 560 nm and an acceptor maximal emission wavelength in a range of 530 to 580 nm.

### Claim 24 (depends on 1)

The fusion protein of claim 1, wherein the FRET acceptor polypeptide comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, 99%, or 100% identical along the length of the amino acid sequence of one or more of SEQ ID NOs:1-3 and identical at the chromophore.

### Claim 25 (depends on 23)

The fusion protein of claim 23, wherein all optional amino acid residues in the FRET acceptor polypeptide are present.

### Claim 26 (depends on 1)

The fusion protein of claim 1, wherein the FRET donor polypeptide has a maximal donor excitation wavelength in a range of 450 to 500 nm and a maximal donor emission wavelength in a range of 480 to 515 nm.

### Claim 27 (depends on 1)

The fusion protein of claim 1, wherein the FRET donor polypeptide comprises an amino acid sequence at least 85%, 87%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, 99%, or 100% identical along the length of the amino acid sequence of SEQ ID NO: 4 and identical at the chromophore.

### Claim 28 (depends on 1)

The fusion protein of claim 1, wherein X3 comprises an ATP binding protein comprising the amino acid sequence at least 65%, 67%, 68%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, 99%, or 100% identical along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS:5-6.

### Claim 29 (depends on 1)

The fusion protein of claim 1, comprising an amino acid sequence at least 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, 99%, or 100% identical along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS:7-11.

### Claim 30

A control fusion protein, comprising a polypeptide of genus X1-X2-X3-X4-X5, wherein:
one of X1 and X5 comprises a fluorescence resonance energy transfer (FRET) acceptor polypeptide having an acceptor excitation wavelength and FRET emission wavelength, and the other of X1 and X5 comprises a FRET donor polypeptide having a donor excitation wavelength and a donor emission wavelength
X2 and X4 independently are optional amino acid linkers; and
X3 comprises a control protein that does not bind to ATP.

### Claim at position 21

-58. (canceled)

### Claim 59 (depends on 1)

A polynucleotide encoding the fusion protein of claim 1.

### Claim 60 (depends on 59)

An expression vector encoding the polynucleotide of claim 59, wherein the polynucleotide is operatively linked to a promoter sequence capable of directing expression of the polynucleotide.

### Claim 61 (depends on 60)

A recombinant host cell comprising the expression vector of claim 60.

### Claim at position 25

-66. (canceled)

### Claim 67 (depends on 1)

A kit comprising:
(a) the fusion protein of claim 1; and
(b) a control fusion protein.

### Claim 68

(canceled)

### Claim 69 (depends on 1)

A method of assaying ATP, comprising:
(a) expressing the fusion protein of claim 1 in one or more first cells, and generating one or more images selected from the group consisting of:
(i) a first fluorescence image generated by detecting fluorescent signals produced by light having the FRET acceptor polypeptide emission wavelength emitted from the one or more first cells upon exposing the one or more first cells to light having the FRET donor polypeptide excitation wavelength; and/or
(ii) a second fluorescence image generated by detecting fluorescent signals produced by light having the FRET acceptor polypeptide emission wavelength emitted from the one or more first cells upon exposing the one or more first cells to light having the FRET acceptor polypeptide excitation wavelength; and/or
(iii) a third fluorescence image generated by detecting fluorescent signals produced by light having the FRET donor polypeptide emission wavelength emitted from the one or more first cells upon exposing the one or more first cells to light having the FRET donor polypeptide excitation wavelength; and
(b) determining a FRET ratio in the one or more first cells by comparing the output of fluorescent signals in the first fluorescent image, the second fluorescent image, and/or the third fluorescent image;
wherein the level of ATP in the one or more first cells is proportional to the determined FRET ratio.

### Claim at position 29

-103. (canceled)
